Krystal Biotech Q2 2026: VYJUVEK Revenue Reaches $119M as Pipeline Advances
KRYS has more than doubled off its 52-week low of $130.5.
Summary
Krystal Biotech reported Q2 2026 revenue of $119.2M, up 24% YoY, and net income of $54.8M. With $845.6M in cash, the company is advancing multiple pipeline programs, including completed enrollment in the IOLITE Phase 3 study.
Key Events · Earnings and Guidance · KRYS
-
VYJUVEK Revenue Grows 24%
Net product revenue reached $119.2 million in Q2 2026, up from $96.0 million a year ago, driven by launches in Europe and Japan.
-
Net Income Jumps 43%
Net income was $54.8 million, or $1.79 per diluted share, compared to $38.3 million, or $1.29 per share, in Q2 2025.
-
Strong Cash Position
Cash, cash equivalents, and short-term investments totaled $845.6 million as of June 30, 2026, sufficient to fund operations for at least 12 months.
-
Pipeline Milestones
Enrollment completed in the IOLITE Phase 3 study for KB803; EMERALD-1 registrational study for KB801 is enrolling; repeat-dose study for KB407 initiated.
Analysis · KRYS · Life Sciences
Krystal Biotech posted a strong second quarter, with VYJUVEK net revenue climbing 24% year-over-year to $119.2 million, fueled by launches in Europe and Japan. Net income surged 43% to $54.8 million, and the balance sheet remains robust with $845.6 million in cash and short-term investments, providing ample runway. On the pipeline front, enrollment in the IOLITE Phase 3 study for KB803 in DEB ocular complications is now complete, and the EMERALD-1 registrational study for KB801 in neurotrophic keratitis is actively enrolling. A new inventorship lawsuit filed in May 2026 concerning KB407 patents introduces some legal uncertainty, though management considers the claims meritless.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRYS was trading at $315.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $130.50 to $382.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.